Market Intelligence, Clinical Progress, and High-Purity Reagents for Diabetic Complications and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for AKR1B1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT & Mutant) | AKR1B1 Recombinant Protein (wild-type and C298A mutant). High purity (>95%), Sequence Verified, Endotoxin <1 EU/µg. Active site integrity preserved for mechanism-of-action studies. | View AKR1B1 Products |
| Gene Delivery | AKR1B1 Lentivirus Premade Particles / ORF cDNA. Full-length ORF for stable cell line construction in HEK293/CHO. | View AKR1B1 Products |
| Research Antibody | Anti-AKR1B1 Antibody (Rabbit Polyclonal / Mouse Monoclonal). Benchmark antibody for Western Blot, IHC, ELISA validation. | View AKR1B1 Products |
| Validator | AKR1B1 siRNA Set (3 unique sequences). For knockdown verification and target engagement specificity checks. | View AKR1B1 Products |
| Selectivity Counter-Screen | AKR1B10 Recombinant Protein. High homology paralog (~71% identity). Essential for off-target liability assessment. | View AKR1B10 Products |
| Extended Homolog Panel | AKR1A1 Recombinant Protein; complete human AKR1 panel (A1, B1, B10, C1–C4) with strict sequence identity verification. | View AKR1A1 Products |
| Pathway Partner | SORD (Sorbitol Dehydrogenase). Downstream polyol pathway enzyme for combination studies. | View SORD Products |
| Pathway Partner | NFE2L2 (Nrf2). Synergistic oxidative stress pathway partner. | View NFE2L2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Selectivity over AKR1B10 & AKR1A1 | Homolog panel proteins strictly Sequence Verified with >95% purity; mass-spec confirmed identity prevents cross-reactivity artifacts. |
| Active Site Conformational Integrity | Catalytic mutant (C298A) and wild-type available; crystallography-grade preparation with NADPH-binding fold preserved. |
| Enzymatic activity & HTS readiness | High-purity AKR1B1 with verified cofactor-binding fold; suitable for NADPH-dependent inhibition assays. |
| Cell-based target engagement & Polyol Pathway Validation | Premade lentivirus particles (10^8 TU/mL) for stable overexpression in HEK293 or cancer cell backgrounds; suitable for sorbitol accumulation assays. |
| False Positives / Off-target artifacts | Validated siRNA included for rescue experiments; endotoxin <1 EU/µg. |
| Pan-AKR Family Off-target Screening | Complete human AKR1 panel (A1, B1, B10, C1–C4) with strict sequence identity verification. |
Live AKR1B1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for AKR1B1 (Aldose Reductase) therapeutics is intensifying, with a strategic pivot from broad aldose reductase inhibition toward highly selective targeting. While first-generation therapies like epalrestat remain standard of care for diabetic neuropathy in Asian markets, the field is increasingly focused on distinguishing AKR1B1 from its oncogenic homolog AKR1B10 to develop tissue-specific therapies. Emerging research highlights AKR1B1's role in inflammatory signaling, epithelial-mesenchymal transition (EMT), cancer metastasis, and chemoresistance. This drives renewed interest in applications beyond diabetic complications, including acute lung injury, solid tumors, and immunometabolism. Current R&D is intensely focused on next-generation small molecules, PROTACs, and combination strategies to eliminate off-target toxicities associated with earlier ARIs. As first-generation therapies establish baselines, the next wave targets multi-indication utility driven by precision selectivity profiles.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor (Classic) | Ono Pharmaceutical (Epalrestat), Daiso Sankyo, Bayer, Abbott | Diabetic neuropathy, diabetic cataracts | Enzymatic inhibition assay (need high-purity >95% active AKR1B1 protein) |
| Isoform-Selective Inhibitor | Preclinical research groups, Otsuka, Janssen | Cancer (NSCLC, liver), inflammatory disease | Dual counter-screen (AKR1B1 vs AKR1B10) with matched specs |
| Targeted Protein Degradation (PROTAC) | Emerging biotechs | Solid tumors (EMT inhibition) | Ternary complex validation (need native-conformation recombinant proteins) |
| Combination Therapies | Various academic/biopharma | Chemo-resistant cancers | Functional rescue assays (need lentivirus for stable overexpression) |
| Gene Silencing | Academic consortia | Inflammatory disease | siRNA validation tools and lentiviral overexpression systems for pathway analysis |
Strategic Assay Recommendations
To develop a best-in-class AKR1B1 inhibitor, the following assay cascade is recommended:
- Primary screening: NADPH consumption enzymatic assay with high-purity recombinant AKR1B1 (TarMart provides >95% purity, sequence verified).
- Selectivity counter-screen: Parallel testing against AKR1B10 and AKR1A1 to calculate selectivity index (>100-fold preferred).
- Cellular engagement: Use TarMart lentivirus to build stable overexpression lines for CETSA or sorbitol accumulation assays.
- Mechanism-of-action: Compare wild-type vs C298A catalytic mutant to distinguish competitive from non-competitive inhibition.
- Off-target safety: Complete AKR1 panel screening to rule out cross-reactivity with other family members.